These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

978 related items for PubMed ID: 14759988

  • 1. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Künzer H, Lichtner RB, Nishino Y, Parczyk K, Sauer G, Gieschen H, Ulbrich HF, Schneider MR.
    J Natl Cancer Inst; 2004 Feb 04; 96(3):210-8. PubMed ID: 14759988
    [Abstract] [Full Text] [Related]

  • 2. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
    Howell SJ, Johnston SR, Howell A.
    Best Pract Res Clin Endocrinol Metab; 2004 Mar 04; 18(1):47-66. PubMed ID: 14687597
    [Abstract] [Full Text] [Related]

  • 3. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, Strum JC, Thatcher GRJ, Norris JD.
    Breast Cancer Res Treat; 2020 Apr 04; 180(3):635-646. PubMed ID: 32130619
    [Abstract] [Full Text] [Related]

  • 4. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL, Yde CW, Laenkholm AV, Rasmussen BB, Duun-Henriksen AK, Bak M, Lykkesfeldt AE, Kirkegaard T.
    BMC Cancer; 2015 Apr 08; 15():239. PubMed ID: 25885472
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Apr 08; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

  • 8. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C, Gajdos C, Cheng D, Jordan VC.
    J Steroid Biochem Mol Biol; 2005 Feb 08; 93(2-5):249-56. PubMed ID: 15860267
    [Abstract] [Full Text] [Related]

  • 9. Approaches targeted to estrogen receptors for treatment of tamoxifen-resistant breast cancer: a brief overview.
    Terakawa N.
    Oncology; 2000 Feb 08; 59 Suppl 1():3-4. PubMed ID: 11096349
    [No Abstract] [Full Text] [Related]

  • 10. Estrogen induces death of tamoxifen-resistant MCF-7 cells: contrasting effect of the estrogen receptor downregulator fulvestrant.
    Planas-Silva MD, Waltz PK, Kilker RL.
    J Steroid Biochem Mol Biol; 2006 Mar 08; 98(4-5):193-8. PubMed ID: 16464573
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
    Lee ES, Schafer JM, Yao K, England G, O'Regan RM, De Los Reyes A, Jordan VC.
    Clin Cancer Res; 2000 Dec 08; 6(12):4893-9. PubMed ID: 11156249
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M, Kodama T.
    In Vivo; 2001 Dec 08; 15(4):319-25. PubMed ID: 11695224
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
    J Natl Cancer Inst; 2004 Jun 16; 96(12):926-35. PubMed ID: 15199112
    [Abstract] [Full Text] [Related]

  • 18. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA.
    Mol Cancer Ther; 2015 Sep 16; 14(9):2035-48. PubMed ID: 26116361
    [Abstract] [Full Text] [Related]

  • 19. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
    Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE.
    J Steroid Biochem Mol Biol; 2003 Mar 16; 84(4):469-78. PubMed ID: 12732292
    [Abstract] [Full Text] [Related]

  • 20. Differences in immunoreactivity of estrogen receptor (ER) in tamoxifen-sensitive and -resistant breast carcinomas: preclinical and first clinical investigations.
    Naundorf H, Jost-Reuhl B, Becker M, Reuhl T, Neumann C, Fichtner I.
    Breast Cancer Res Treat; 2000 Mar 16; 60(1):81-92. PubMed ID: 10845812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.